Home > DNA/RNA Synthesis & > Capecitabine

Capecitabine

卡培他滨,RO 09-1978

Capecitabine是一种治疗肿瘤选择性的氟嘧啶氨基甲酸酯，具有较高的瘤内5-FU水平，且毒性比5-FU低。

目录号
EY1193
EY1193
EY1193
纯度
99.51%
99.51%
99.51%
规格
50 mg
100 mg
500 mg
原价
200
300
500
售价
200
300
500
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Capecitabine is a tumor-selective fluoropyrimidine carbamate, which achieves higher intratumoral 5-FU level with lower toxicity than 5-FU.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    0-1 mM

  • 动物实验

    每天≤1.5 mM/kg 口服处理

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Ciccolini J, et al. Mol Cancer Ther. 2002, 1(11), 923-927.

    分子式
    C15H22FN3O6    		 分子量
    359.35    		 CAS号
    154361-50-9    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    ≥70 mg/mL    		 Water
    25 mg/mL    		 Ethanol
    ≥70 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01128842 Advanced Malignant Solid Tumors Drug: Neratinib + Capecitabine Puma Biotechnology, Inc. Phase 1 2010-04-01 2012-05-10
    NCT01050985 Advanced Solid Tumors Drug: Temsirolimus and capecitabine Georgetown University|Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 2010-07-01 2014-02-12
    NCT02491697 Breast Cancer Biological: DC-CIK Immunotherapy|Drug: Capecitabine Monotherapy The First People's Hospital of Changzhou Phase 2 2016-02-01 2016-02-21
    NCT02915172 Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract Drug: Lenvatinib|Drug: Capecitabine M.D. Anderson Cancer Center|Eisai Inc. Phase 1 2016-12-01 2016-09-23
    NCT00532714 Breast Cancer Metastatic Drug: Irinotecan plus capecitabine National Cancer Center, Korea Phase 2 2006-08-01 2011-12-27
    NCT00496366 Breast Cancer|Metastatic Breast Cancer|Advanced Breast Cancer|HER2/Neu-positive Breast Cancer Drug: Capecitabine|Drug: Lapatinib Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey Phase 2 2007-07-23 2017-03-20
    NCT00169000 Metastatic Breast Cancer Drug: Capecitabine|Drug: Docetaxel Dartmouth-Hitchcock Medical Center|Hoffmann-La Roche Phase 1 2003-01-01 2009-08-04
    NCT00263705 Elderly Patients|Breast Cancer Drug: Adjuvant capecitabine|Drug: capecitabine in aduvant setting Jules Bordet Institute Phase 2 2003-01-01 2011-02-23
    NCT01306630 Advanced Solid Tumors|Locally Advanced or Metastatic Breast or Colorectal Cancer Drug: tivozanib (AV-951) and capecitabine (Xeloda) AVEO Pharmaceuticals, Inc. Phase 1 2010-11-01 2014-01-23
    NCT00697502 Solid Tumors Drug: Capecitabine National University Hospital, Singapore Phase 1 2007-05-01 2012-10-31
    NCT01463982 Solid Tumor|Advanced Cancer Drug: Oratecan and Capecitabine Hanmi Pharmaceutical Company Limited Phase 1 2010-12-01 2015-04-08
    NCT01891227 Breast Cancer Drug: Capecitabine|Drug: Bendamustine Arbeitsgemeinschaft medikamentoese Tumortherapie Phase 2 2013-08-01 2016-12-22
    NCT00591188 Carcinoma, Renal Cell Drug: capecitabine, interferon-alpha Kidney Cancer Research Bureau Phase 2 2006-12-01 2009-04-30
    NCT00618124 Solid Tumors|Breast Cancer|Neoplasms Drug: SU011248; Capecitabine Pfizer Phase 1 2005-05-01 2010-04-29
    NCT00961571 Metastatic Colorectal Cancer Drug: sunitinib and capecitabine Georgetown University|Pfizer Phase 2 2009-08-01 2014-02-04
    NCT00585078 Pancreatic Cancer Drug: Capecitabine|Drug: Oxaliplatin Beth Israel Deaconess Medical Center|Sanofi|Dana-Farber Cancer Institute Phase 2 2004-04-01 2017-02-23
    NCT00960544 Breast Cancer Drug: Capecitabine M.D. Anderson Cancer Center|Myriad Genetic Laboratories, Inc. Phase 2 2017-06-01 2017-03-21
    NCT02754011 Breast Cancer Drug: Combination of ribociclib + capecitabine UNICANCER|Novartis Phase 1 2017-01-01 2017-02-09
    NCT01928680 Metastatic Breast Cancer Drug: Cisplatin/Capecitabine Chinese Academy of Medical Sciences Phase 2 2012-11-01 2015-02-04
    NCT01067053 Metastatic Colorectal Cancer Drug: bevacizumab, capecitabine, oxaliplatin Grupo Espanol Multidisciplinario del Cancer Digestivo Phase 2 2009-11-01 2014-01-08

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：